Much of the focus for making CGTs accessible and commercially viable has looked downstream at manufacturing, logistics, geography, centralization, and even intellectual property. However, the vast majority of ex vivo advanced therapies share the same starting point — blood — and the future of CGT rests on our ability to improve how we get what we need from patients’ and donors’ blood.